Avicanna Reports Q1 2026 Financial Statements

• Avicanna reported Q1 2026 financial results with record quarterly revenue of $6.68 million, a 6% year-over-year increase.
• Gross profit reached $3.84 million with consolidated gross margins at 58%, slightly up from 57% in the prior year period.
• Adjusted EBITDA reported a loss of $0.15 million, contrasting sharply with an income of $0.43 million in Q1 2025.
• Working capital deficit was reduced significantly by $0.96 million to $0.32 million from a $1.28 million deficit in the prior year period.
• Commercial expansion included a 42% year-over-year increase in Avicanna-branded product unit sales via MyMedi.ca platform.
• Clinical milestones include initiation of a Phase I dose-finding clinical trial for oral THC at the University of Calgary and first commercial export of organic certified flower to Australia by subsidiary SMGH.

• The earnings release confirms revenue growth but highlights a regression in quarterly profitability compared to Q1 2025, which is concerning given the FY 2025 narrative of near break-even status.
• While working capital improvement reduces immediate liquidity risk, the return to an EBITDA loss after a profitable Q4 2025 suggests operational leverage has not yet stabilized.
• The news does not contain genuinely new strategic shifts or M&A activity that would alter the fundamental valuation thesis; it is primarily an execution update.
• Given the stock price is at multi-year lows ($0.12) and profitability metrics have regressed year-over-year, the market impact is likely muted to negative as investors weigh revenue gains against margin erosion.

• Avicanna operates an integrated commercial and pharmaceutical pipeline focused on medical cannabis and cannabinoid therapeutics.
• Flagship Project: MyMedi.ca platform, a digital health service providing physician-authorized medical cannabis with pharmacist-led support.
• Subsidiary SMGH (Santa Marta Golden Hemp SAS) handles international exports of organic certified flower from Colombia to 24 global markets.
• R&D Pipeline includes proprietary drug delivery platforms (PwdRx™, AVCN319301b capsules) and clinical trials for anxiety, stress, and arthritic pain.